Our results suggest that the pharmacological inactivation of HIF-1α, CREB, p53 or NRF2 could be beneficial for the treatment of obesity and type 2 diabetes in humans. This evidence concerns the gene TP53 and obesity due to melanocortin 4 receptor deficiency.